Mycophenolate mofetil (250mg) : Ingredients, Benefits, Dosage, Precautions and More.

MYCOPLASM M 250

Mycophenolate mofetil (250mg)

MYCOPLASM M 250, containing 250mg of Mycophenolate Mofetil, is a pivotal medication used in immunosuppressive therapy, particularly in transplant medicine and the management of autoimmune diseases. This medication plays a crucial role in modulating the immune response, ensuring better outcomes for patients undergoing immune system control.

How MYCOPLASM M 250 Works Mycophenolate Mofetil, the active ingredient in MYCOPLASM M 250, inhibits the enzyme inosine monophosphate dehydrogenase, essential for the production of guanosine nucleotides in immune cells. By interfering with this process, MYCOPLASM M 250 reduces the proliferation of T and B cells, leading to immunosuppression and preventing rejection in transplant patients or controlling autoimmune activity.

Benefits of MYCOPLASM M 250

• Effective Immunosuppression: MYCOPLASM M 250 effectively suppresses the immune system, reducing the risk of rejection in transplant recipients and managing autoimmune diseases like lupus nephritis and rheumatoid arthritis.
• Improved Graft Survival: Lower rates of acute rejection and improved long-term graft survival in transplant patients.
• Disease Management: Helps control disease activity, inflammation, and symptoms in autoimmune conditions, leading to enhanced quality of life.

Why Choose MYCOPLASM M 250? MYCOPLASM M 250 is a trusted and proven medication in immune system modulation, with a track record of success in transplant medicine and autoimmune disease management. Its targeted action on immune cells makes it a preferred choice for patients and healthcare providers.

Usage and Dosage The dosage of MYCOPLASM M 250 varies based on the specific condition being treated, the patient's weight, and other factors. It is essential to follow the prescribing physician's instructions meticulously and undergo regular monitoring to ensure optimal therapeutic outcomes and safety.

Safety and Precautions While generally well-tolerated, MYCOPLASM M 250 may cause side effects such as gastrointestinal disturbances, bone marrow suppression, and increased susceptibility to infections. Close monitoring and adherence to prescribed guidelines are crucial to managing potential risks.

Conclusion MYCOPLASM M 250 is a cornerstone medication in immune system control, offering a potent and targeted approach to preventing organ rejection in transplant patients and managing autoimmune diseases effectively. With its established efficacy and safety profile, MYCOPLASM M 250 plays a critical role in improving patient outcomes and promoting better long-term health in individuals undergoing immunosuppressive therapy.

A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.  For further information:  EMAIL:  info@sterispharma.com  / contact@sterispharma.com     CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668   BUY NOW